LOUISVILLE, Colo.– Biodesix, Inc. (Nasdaq: BDSX) announced it will release its Q3 financial results on November 1, 2024, before markets open. Management will discuss these results in a conference call and webcast at 8:30 a.m. ET that same day.
Listeners can register for the webcast [here]. Analysts needing to ask questions can use a different link. A replay will be available on the investor website about two hours after the call. Please join 15 minutes early.
About Biodesix
Biodesix specializes in diagnostic solutions for lung diseases, offering five Medicare-covered tests. Their Nodify Lung® test assesses malignancy risk in lung nodules, while the IQLung™ tests are designed for lung cancer patients, helping guide treatment decisions. The company also collaborates with biopharmaceutical firms for biomarker research and diagnostic test development. For more details, visit biodesix.com.
Important Notice
This release contains forward-looking statements with risks and uncertainties as protected under the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly due to various factors. Readers should not rely solely on these statements. More information is included in the Risk Factors section of Biodesix’s latest annual report filed on March 1, 2024.
View the full version on businesswire.com: https://www.businesswire.com/news/home/20241018266313/en/
Media Contact:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investor Contact:
Chris Brinzey
chris.brinzey@westwicke.com
(339) 970-2843
Source: Biodesix, Inc.
`
